On August 7, Guardant Health Inc. rose 5.39% in regular trading, trading near $165.98/share with turnover of $44.12 million, extending the upward trend following its recent earnings release.

The move continues to be driven by the company's strong Q2 results reported on July 30. Revenue came in at $335.0 million, up 44.3% year-over-year and significantly exceeding the analyst consensus estimate of $314.2 million. The company simultaneously raised its full-year revenue guidance to $1.34-$1.36 billion from a prior range of $1.30-$1.32 billion, well above the Street estimate of $1.31 billion. Adjusted loss per share narrowed to $0.42 from $0.44 a year earlier.

Analyst sentiment has strengthened alongside the results. RBC Capital Markets raised its price target to $200 from $185 while maintaining an Outperform rating. The stock carries a consensus Buy rating with a mean price target of $191.09. Recent catalysts including multiple FDA approvals for Guardant360 CDx and Shield blood test inclusion in American Cancer Society guidelines have further reinforced the bullish thesis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)